A total of 43 patients with CLDN18.2-positive advanced PDAC (≥60% tumor cells with membranous staining intensity ≥1+ by IHC) received IBI343 6 mg/kg Q3W monotherapy. All participants had previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback